The derived therapeutic implication is that drugs targeting RANKL, including Denosumab (which is currently only approved for the prevention of bone fracture in patients with breast and prostate cancer), could be efficacious not only to treat the bone symptoms associated with bone cancer metastasis, but also to prevent or limit the development of the disease itself, by reducing breast cancer bone metastasis and/or the activation of dormant breast cancer cells, if administered as adjuvant therapy. Here, TNFSF11 is linked to bone neoplasm.